ESC Professional Premium Access

Should we initiate oral anticoagulants for patients with atrial fibrillation staying well without oral anticoagulants for years?

Congress Presentation

About the speaker

Doctor Tze-Fan Chao

Taipei Veterans General Hospital, Taipei (Taiwan)
3 presentations
0 follower

6 more presentations in this session

Associations of soluble fms-like tyrosine kinase-1 with cardiovascular events and stroke in patients with atrial fibrillation and suspected or known coronary artery disease: The EXCEED-J Study

Speaker: Doctor K. Hasegawa (Kyoto, JP)


Prediction of atrial fibrillation in patients with embolic stroke with undetermined source using electrocardiogram deep learning algorithm and clinical risk factors

Speaker: Associate Professor J. Lee (Seongnam, KR)


We all know A and B, but what about C? Exploring the management of modifiable risk factors in patients with atrial fibrillation.

Speaker: Miss D. Verhaert (Nijmegen, NL)


Incidence and risk factors for major bleeding events in atrial fibrillation patients on direct oral anticoagulant therapy: data from the National Patient-Centered Clinical Research Network

Speaker: Doctor K. Arps (Durham, US)


The association between dyslipidaemia treatment and the risk of clinical events in edoxaban-treated patients with atrial fibrillation: insights from the 2-year follow-up of ETNA-AF-Europe

Speaker: Doctor T. de Vries (Amsterdam, NL)


Access the full session

Stroke prevention in atrial fibrillation

Speakers: Doctor T. Chao, Doctor K. Hasegawa, Associate Professor J. Lee, Miss D. Verhaert, Doctor K. Arps...

About the event


ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb